Acumen pharmaceuticals to report second quarter results on august 13, 2024

Newton, mass., aug. 06, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, today announced that the company will report second quarter 2024 financial results on tuesday, august 13, 2024. the company will host a conference call and live audio webcast at 8:00 a.m. et to provide a business and financial update.
ABOS Ratings Summary
ABOS Quant Ranking